Search Results - "Blons, H."

Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network by Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., Escande, F., Lizard, S., Pretet, J.-L., Rouquette, I., de Crémoux, P., Solassol, J., de Fraipont, F., Bièche, I., Cayre, A., Favre-Guillevin, E., Tomasini, P., Wislez, M., Besse, B., Legrain, M., Voegeli, A.-C., Baudrin, L., Morin, F., Zalcman, G., Quoix, E., Blons, H., Cadranel, J.

“…There is scarce data available about epidermal growth factor receptor (EGFR) mutations other than common exon 19 deletions and exon 21 (L858R) mutations. EGFR…”
Get full text

Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) program by Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., Monnet, I., Rouquette, I., Fraboulet-Moreau, S., Lemoine, A., Pouessel, D., Mosser, J., Vaylet, F., Langlais, A., Missy, P., Morin, F., Moro-Sibilot, D., Cadranel, J., Barlesi, F., Beau-Faller, M.

“…EGFR mutations cause inconsistent response to EGFR tyrosine-kinase inhibitors (TKI). To better understand these features, we reviewed all cases of EGFR-mutated…”
Get full text

Oncogenic mutations as predictive factors in colorectal cancer by Lièvre, A, Blons, H, Laurent-Puig, P

“…The anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies cetuximab and panitumumab have been demonstrated to be new therapeutic options for…”
Get full text

RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study by Bachet, J.B., Bouché, O., Taieb, J., Dubreuil, O., Garcia, M.L., Meurisse, A., Normand, C., Gornet, J.M., Artru, P., Louafi, S., Bonnetain, F., Thirot-Bidault, A., Baumgaertner, I., Coriat, R., Tougeron, D., Lecomte, T., Mary, F., Aparicio, T., Marthey, L., Taly, V., Blons, H., Vernerey, D., Laurent-Puig, P.

“…RAS mutations are currently sought for in tumor samples, which takes a median of almost 3weeks in western European countries. This creates problems in clinical…”
Get full text

Molecular classification of pulmonary sarcomatoid carcinomas suggests new therapeutic opportunities by Pécuchet, N., Vieira, T., Rabbe, N., Antoine, M., Blons, H., Cadranel, J., Laurent-Puig, P., Wislez, M.

“…Pulmonary sarcomatoid carcinoma (SC) is a rare disease with poor prognosis and with strong inter- and intratumor heterogeneity. However, molecular…”
Get full text

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project by Blons, H., Oudart, J.-B., Merlio, J.-P., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P.‐P., Fraboulet-Moreau, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A, Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., Beau‐Faller, M.

“…•Response to EGFR TKI is heterogeneous among patients with EGFR mutated NSCLC.•Routine use of NGS enables co-mutations detection that may impact response to…”
Get full text

Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours by Cros, J., Sbidian, E., Hans, S., Roussel, H., Scotte, F., Tartour, E., Brasnu, D., Laurent-Puig, P., Bruneval, P., Blons, H., Badoual, C.

“…Malignant tumours of the salivary glands (MSGT) are rare and pleomorphic entities. Patients with advanced disease may benefit from targeted therapy; however,…”
Get full text

Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset by Blons, H., Emile, J.F., Le Malicot, K., Julié, C., Zaanan, A., Tabernero, J., Mini, E., Folprecht, G., Van Laethem, J.L., Thaler, J., Bridgewater, J., Nørgård-Petersen, L., Van Cutsem, E., Lepage, C., Zawadi, M.A., Salazar, R., Laurent-Puig, P., Taieb, J.

“…The prognostic value of KRAS mutations in colon adenocarcinoma is controversial. We examined this question as an ancillary study of the PETACC8 phase III…”
Get full text

Chemoradiotherapy efficacy is predicted by intra-tumour CD8+/FoxP3+ double positive T cell density in locally advanced N2 non–small-cell lung carcinoma by Boulle, G., Velut, Y., Mansuet-Lupo, A., Gibault, L., Blons, H., Fournel, L., Boni, A., Cremer, I., Wislez, M., Duchatelle, V., Trédaniel, J., Hammond, S.A., Herbst, R., Alifano, M., Giraud, P., Damotte, D.

“…Radiotherapy is a standard of care for locally advanced stage III N2 non–small-cell lung carcinoma (NSCLC) combined with surgery/chemotherapy. Radiotherapy is…”
Get full text

Clinical, biochemical and epidemiological features of macro-AST preceding inflammatory bowel disease diagnosis by several years by Nadour, Z, Rosenbaum, B, Blons, H, Loriot, M A, Paul, J-L, Pallet, N

“…An isolated elevation of aspartate aminotransferase (AST) is a diagnostic issue. Macro-aspartate aminotransferase (macro-AST) corresponds to the formation of…”
Get full text

Panitumumab combined with irinotecan for patients with KRAS wild-type metastatic colorectal cancer refractory to standard chemotherapy: a GERCOR efficacy, tolerance, and translational molecular study by André, T., Blons, H., Mabro, M., Chibaudel, B., Bachet, J-B., Tournigand, C., Bennamoun, M., Artru, P., Nguyen, S., Ebenezer, C., Aissat, N., Cayre, A., Penault-Llorca, F., Laurent-Puig, P., de Gramont, A.

“…The purpose of this study was to evaluate the combination of panitumumab and irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory…”
Get full text

Expression of pEGFR and pAKT as response-predictive biomarkers for RAS wild-type patients to anti-EGFR monoclonal antibodies in metastatic colorectal cancers by Harlé, A, Salleron, J, Perkins, G, Pilati, C, Blons, H, Laurent-Puig, P, Merlin, J L

“…Background: RAS wild-type (RAS w/t ) tumours have been associated with better outcomes in patients with metastatic colorectal cancer (mCRC) treated with…”
Get full text

Joined analysis of sarcomatoid carcinoma (SC) mutational profiles: Comparison of lung versus head and neck cancer by Pecuchet, N., Touachi, R., Ben Lakhdar, A., Fallet, V., Rabbe, N., Blons, H., Lemoine, A., Antoine, M., Tenam, S., Laurent-Puig, P., Wislez, M.

Get full text

PG 1.4 Molecular differences between colon and rectal cancer by Pilati, C, Blons, H, Laurent-Puig, P

Get full text

Circulating tumor DNA (ctDNA) in advanced non-small cell lung cancer (NSCLC) from HIV-infected patients is associated to shorter overall survival (OS): Results from phase II trial (IFCT-1001 CHIVA) by Wislez, M., Blons, H., Domblides, C., Barlesi, F., Mazieres, J., Monnet, I., Kiakouama Maleka, L., Quantin, X., Taillade, L., Lena, H., Fraisse, P., Janicot, H., Audigier Valette, C., Amour, E., Langlais, A., Rabbe, N., Cadranel, J., Laurent puig, P., Lavolé, A.

Get full text

Molecular heterogeneity assessment by NGS in non-small cell lung cancer (NSCLC) harboring EGFR mutations: Results of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France study by Blons, H., Oudart, J.-B., Merlio, J.-P., Hominal, S., de Fraipont, F., Debieuvre, D., Escande, F., Audigier Valette, C., Bringuier, P.-P., Moreau Fraboulet, S., Ouafik, L., Moro-Sibilot, D., Lemoine, A., Langlais, A., Missy, P., Morin, F., Souquet, P.-J., Barlesi, F., Cadranel, J., Beau-Faller, M.

Get full text

Clinicopathological significance of mitochondrial D-Loop mutations in head and neck carcinoma by LIEVRE, A, BLONS, H, HOULLIER, A. M, LACCOURREYE, O, BRASNU, D, BEAUNE, P, LAURENT-PUIG, P

“…Mitochondrial DNA mutations have been reported in several types of tumours, including head and neck squamous cell carcinoma (HNSCC). The noncoding region of…”
Get full text

2167 Microsatellite status predicts BRAF V600E and KRAS exon 2 mutations prognostic value in stage III colon cancers (CC) patients treated with adjuvant FOLFOX +/- cetuximab. A post-hoc analysis of the PETACC8 trial by Taieb, J, Zaanan, A, Malicot, K. Le, Julie, C, Blons, H, Mineur, L, Tabernero, J, Mini, E, Folprecht, G, Laethem, J.L. Van, Lepage, C, Emile, J.F, Laurent-Puig, P

Get full text

468 Validity of next generation sequencing in routine care for non-small cell lung cancer diagnosis by Legras, A, Pecuchet, N, Tallet, A, Guyard, A, Mansuet-Lupo, A, Prieur, E. Giroux-Le, Giraudet, V, Gibault, L, Damotte, D, Julie, C, Alifano, M, Pimpec-Barthes, F. Le, Laurent-Puig, P, Fabre, E, Blons, H

Get full text

208 Different prognostic impact of STK11 mutations in Non-Small-Cell Lung Cancer (NSCLC) illustrates the switch from a tumor suppressor to an oncogene by Pecuchet, N, Laurent-Puig, P, Mansuet-Luppo, A, Legras, A, Alifano, M, Pallier, K, Didelot, A, Gibault, L, Danel, C, Just, P.A, Le Pimpec-Barthes, F, Damotte, D, Fabre, E, Blons, H

Get full text